Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
April 17, 2024 01:15 ET
|
Novartis Pharma AG
Continuous Kesimpta® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years) treatment-naïve people living with relapsing multiple sclerosis (RMS) in an analysis...
Hint Announces Partnership with E Powered Benefits to Enable Better Access to Direct Primary Care Through Performance Health Plans
January 11, 2024 10:00 ET
|
Hint Health
San Francisco, CA, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Hint Health, the leading provider of membership management, billing, and employer direct contracting infrastructure for Direct Primary Care (DPC)...
Sandoz presents compelling investment proposition as standalone company at Capital Markets Day
June 08, 2023 01:15 ET
|
Novartis Pharma AG
Sandoz well positioned to deliver continued mid-single digit sales growth; core EBITDA margin of 24-26% and Free Cash Flow to more than double over mid term European champion committed to further...
Novartis unveils new focused strategy, underpinned by eight potential multi-billion dollar peak sales brands & deep pipeline, at Meet the Management event
September 22, 2022 01:15 ET
|
Novartis Pharma AG
Transformation to pure-play Innovative Medicines company nears completion Focusing strategy on five core Therapeutic Areas, key technology platforms, and the US Advancing eight...
Novartis renews commitment to neglected tropical disease and malaria elimination, investing USD 250 million over five years to research and develop new treatments
June 22, 2022 20:01 ET
|
Novartis Pharma AG
Novartis endorses the Kigali Declaration on neglected tropical diseases, pledging USD 250 million to advance R&D of new treatments against NTDs and malaria over five yearsCommitment includes USD...
Sandoz Application for proposed biosimilar adalimumab’s high concentration formulation accepted by EMA
June 17, 2022 01:15 ET
|
Novartis Pharma AG
Submission supported by comprehensive analytical and clinical data from new Phase I bridging pharmacokinetics studyAdalimumab’s high-concentration 100 mg/mL formulation aims to provide an enhanced yet...
Aktionärinnen und Aktionäre von Novartis heissen an der ordentlichen Generalversammlung alle Anträge des Verwaltungsrats gut
March 04, 2022 09:19 ET
|
Novartis Pharma AG
Die Aktionäre genehmigen die 25. Dividendenerhöhung in Folge auf CHF 3.10 (+3,3 %) pro Aktie für 2021; dies entspricht einer Rendite von 3.9 %1 und einer Ausschüttung von rund 57 % des freien...
Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d’administration lors de l’Assemblée générale ordinaire
March 04, 2022 09:19 ET
|
Novartis Pharma AG
Les actionnaires approuvent la 25e augmentation consécutive du dividende qui passe à CHF 3.10 (+3,3%) par action pour 2021; représentant un rendement de 3.9%1 et une distribution du free cash-flow...
Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
March 04, 2022 09:19 ET
|
Novartis Pharma AG
Shareholders approve 25th consecutive dividend increase to CHF 3.10 (+3.3%) per share for 2021; representing a 3.9% yield1 and approximately 57% payout of free cash flowShareholders confirm Dr. Joerg...
Novartis to acquire Gyroscope Therapeutics, adding a one-time gene therapy that could transform care for geographic atrophy, a leading cause of blindness
December 22, 2021 02:00 ET
|
Novartis Pharma AG
There are no currently approved therapies impacting disease progression for the up to 8 million people suffering from geographic atrophy (GA)1,2 Acquisition will add GT005 to the Novartis portfolio,...